Ogden Christopher's Form 4 filing
CytomX Therapeutics, Inc. (CTMX) · filed Jun 17, 2025
- Accession no.
- 0001610717-25-000236
- Filed
- Jun 17, 2025
- Trade date
- Jun 13-16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $33.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ogden ChristopherCIK 0001914523 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | Common Stock | SSaleDisposed | −1,641 | $2.95 | −$4,840.95 | 199,385 | Direct | |
| Jun 13, 2025 | Common Stock | MOption exerciseAcquired | +37,500 | $0.00 | $0 | 236,885 | Direct | |
| Jun 16, 2025 | Common Stock | SSaleDisposed | −10,614 | $2.69 | −$28,551.66 | 226,271 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | Common Stock | MOption exerciseDisposed | −37,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.